Edgewise Therapeutics
EWTX
214 hedge funds and large institutions have $3.72B invested in Edgewise Therapeutics in 2026 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 65 increasing their positions, 66 reducing their positions, and 25 closing their positions.
76% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 25
69% more call options, than puts
Call options by funds: $18.7M | Put options by funds: $11.1M
23% more capital invested
Capital invested by funds: $3.02B → $3.72B (+$699M)
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
8% more funds holding
Funds holding: 199 → 214 (+15)
2% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 66
4.57% less ownership
Funds ownership: 115.07% → 110.5% (-4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$38.9M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$23.8M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$19.8M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$15.6M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$82.6M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$23.2M |
| 3 |
Morgan Stanley
New York
|
-$19.2M |
| 4 |
DM
Deerfield Management
New York
|
-$19M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$16.5M |
EWTX Hedge Fund Activity: Q1 2026 in Review
214 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q1 2026, worth a combined $3.72B — up 23% from $3.02B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new EWTX positions and 25 closed out — a net gain of 19 holders — while 65 added to existing stakes and 66 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $38.9M. The largest seller was Braidwell, cutting an estimated $82.6M.
- 214 institutional investors held Edgewise Therapeutics (EWTX) as of Q1 2026, up from 199 in Q4 2025.
- Funds reported $3.72B of Edgewise Therapeutics stock for Q1 2026, up 23% quarter-over-quarter.
- 44 funds opened new Edgewise Therapeutics positions in Q1 2026 and 25 closed out, a net change of +19 holders.
- The largest Edgewise Therapeutics buyer in Q1 2026 was Janus Henderson Group, an estimated $38.9M added.
- The largest Edgewise Therapeutics seller in Q1 2026 was Braidwell, an estimated $82.6M sold.
Based on aggregated 13F filings for Q1 2026.